Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN3A | Q9NY46 | 7/20 | 0.65 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.65 |
| ▸ | MAOB | P27338 | 6/20 | 0.57 |
| ▸ | PARP15 | Q460N3 | 2/20 | 0.57 |
| ▸ | PARP10 | Q53GL7 | 2/20 | 0.57 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.57 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.47 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.47 |
| ▸ | SCN1A | P35498 | 1/20 | 0.47 |
| ▸ | SCN4A | P35499 | 1/20 | 0.47 |
| ▸ | SCN7A | Q01118 | 1/20 | 0.47 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.47 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.47 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.47 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ralfinamide SCHEMBL5567624 | 0.91 | SCN9A (0.82) | SCN3ASCN9AMAOBPARP15PARP10 | |
| Ralfinamide SCHEMBL5567626 | 0.91 | SCN9A (0.82) | SCN3ASCN9AMAOBPARP15PARP10 | |
| SCHEMBL5185026 | 0.87 | SCN3A (0.61) | SCN3ASCN9AMAOBPARP15PARP10 | |
| SCHEMBL28404312 | 0.83 | SCN3A (0.56) | SCN3ASCN9AMAOBPARP15PARP10 | |
| SCHEMBL3064569 | 0.83 | MAOB (0.58) | SCN9AMAOBPARP10 | |
| SCHEMBL8935443 | 0.81 | MAOB (0.60) | SCN3ASCN9AMAOBPARP15PARP10 | |
| SCHEMBL7460590 | 0.80 | SCN3A (0.71) | SCN3ASCN9AMAOBPARP15PARP10 | |
| SCHEMBL1067948 | 0.80 | MAOB (0.65) | SCN9AMAOBPARP10 | |
| SCHEMBL5684437 | 0.80 | SCN3A (0.55) | SCN3ASCN9AMAOBPARP15PARP10 | |
| SCHEMBL964219 | 0.79 | SCN3A (1.00) | SCN3ASCN9AMAOBPARP15PARP10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 105 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2977046-A1 | ALPHA-AMINOAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF COGNITIVE DISORDERS | Newron Pharmaceuticals S.p.A. (IT) | 2016-01-27 | — | — | EP | claimed |
| US-8697738-B2 | Alpha-aminoamide derivatives useful in the treatment of addictive disorders | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2014-04-15 | — | — | US | claimed |
| US-20130303568-A1 | Substituted 2-Aminoacetamides and the Use Thereof | PURDUE NEUROSCIENCE COMPANY (US) | 2013-11-14 | — | — | US | claimed |
| US-20130217747-A1 | ALPHA-AMINOAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF RESTLESS LEGS SYNDROME | NEWRON PHARM SPA (US) | 2013-08-22 | — | — | US | claimed |
| US-8426431-B2 | Substituted 2-aminoacetamides and the use thereof | PURDUE NEUROSCIENCE COMPANY (US) | 2013-04-23 | — | — | US | claimed |
| EP-2201945-B1 | Use of substituted 2-aminoacetamides for treating or ameliorating anxiety | PURDUE NEUROSCIENCE COMPANY (US) | 2013-03-06 | — | — | EP | claimed |
| EP-2201944-B1 | Use of substituted 2-aminoacetamides for treating, preventing or ameliorating manic depression | PURDUE NEUROSCIENCE COMPANY (US) | 2012-05-23 | — | — | EP | claimed |
| EP-2343064-A1 | Alpha-aminoamide derivatives useful in the treatment of cognitive disorders | Newron Pharmaceuticals S.p.A. (IT) | 2011-07-13 | — | — | EP | claimed |
| EP-1900362-B1 | Alfa-aminoamide derivatives useful in the treatment of addictive disorders | NEWRON PHARM SPA (IT) | 2011-01-12 | — | — | EP | claimed |
| EP-1032377-B1 | SUBSTITUTED 2-AMINOACETAMIDES AND THE USE THEREOF | PURDUE NEUROSCIENCE COMPANY (US) | 2010-11-17 | — | — | EP | claimed |
| EP-1557166-A1 | Alpha-aminoamide derivatives useful in the treatment of lower urinary tract disorders | Newron Pharmaceuticals S.p.A. (IT) | 2005-07-27 | — | — | EP | claimed |
| WO-2005018627-A1 | ALPHA-AMINOAMIDE DERIVATIVES USEFUL AS ANTI-INFLAMMATORY AGENTS | NEWRON PHARMACEUTICALS, SPA (IT) | 2005-03-03 | — | — | WO | claimed |
| US-20030130295-A1 | Substituted 2-aminoacetamides and the use thereof | EURO-CELTIQUE S.A. | 2003-07-10 | — | — | US | claimed |
| US-6479484-B1 | SUBSTITUTED 2-AMINOACETAMIDES AND THE DISCOVERY THAT THESE COMPOUNDS ACT AS BLOCKERS OF SODIUM CHANNELS; PAIN RELIEVERS, TREATMENT OF ARRYTHMIA, LOCAL ANESTHETICS | EURO-CELTIQUE S.A. (LU) | 2002-11-12 | — | — | US | claimed |
| US-20020016464-A1 | Substituted 2-aminoacetamides and the use thereof | EURO-CELTIQUE S.A. | 2002-02-07 | — | — | US | claimed |
| EP-0842143-B1 | 2-(4-SUBSTITUTED)-BENZYLAMINO-2-METHYL-PROPANAMIDE DERIVATIVES | NEWRON PHARM SPA (IT) | 2001-06-13 | — | — | EP | claimed |
| EP-1032377-A1 | SUBSTITUTED 2-AMINOACETAMIDES AND THE USE THEREOF | Euro-Celtique S.A. (LU) | 2000-09-06 | — | — | EP | claimed |
| US-5945454-A | 2-(4-substituted)-benzylamino-2-methyl-propanamide derivatives | PHARMACIA & UPJOHN, S.P.A. (IT) | 1999-08-31 | — | — | US | claimed |
| EP-0842143-A1 | 2-(4-SUBSTITUTED)-BENZYLAMINO-2-METHYL-PROPANAMIDE DERIVATIVES | PHARMACIA & UPJOHN S.p.A. (IT) | 1998-05-20 | — | — | EP | claimed |
| WO-1997005102-A1 | 2-(4-SUBSTITUTED)-BENZYLAMINO-2-METHYL-PROPANAMIDE DERIVATIVES | PHARMACIA & UPJOHN S.P.A. (IT) | 1997-02-13 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130303568-A1 | Substituted 2-Aminoacetamides and the Use Thereof | SLC1A2, GAP43, SCN2A | SCN3A 17/4885SCN9A 80/4885MAOB 245/4885 |
| US-20130217747-A1 | ALPHA-AMINOAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF RESTLESS LEGS SYNDROME | AADAT, PNMT, BCAT2 | SCN3A 372/4885SCN9A 946/4885MAOB 53/4885 |
| US-20020016464-A1 | Substituted 2-aminoacetamides and the use thereof | SLC1A2, SLC1A1, SCN2A | SCN3A 14/4885SCN9A 90/4885MAOB 801/4885 |
| US-20030130295-A1 | Substituted 2-aminoacetamides and the use thereof | SLC1A2, GAP43, SCN2A | SCN3A 10/4885SCN9A 57/4885MAOB 718/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.